Analysis of current regulatory requirements for the quality of live bacterial vaccines and prospects for the improvement of vaccine quality control methods
T. I. Nemirovskaya, С. А. Алексеева, I. V. Kasina, Н. В. Александрова(Onze Lieve Vrouwziekenhuis Hospital)
Biological Products Prevention Diagnosis Treatment
December 22, 2024
Cited by 0
Related Papers
Whole-Genome Sequence of Mycobacterium bovis BCG-1 (Russia)
|Genome Announcements|2015|9
Sepsis in Latvia—Incidence, Outcomes, and Healthcare Utilization: A Retrospective, Observational Study
|Healthcare|2024|2
Specific Aspects of Tuberculin Products Standardisation
|Biological Products Prevention Diagnosis Treatment|2019|1
Using Shewhart charts to monitor quality characteristics of preventive vaccines for tuberculosis
|Biological Products Prevention Diagnosis Treatment|2023|1
A diagnostic dilemma: distinguishing a sulfasalazine induced DRESS hypersensitivity syndrome from a CD30 + lymphoma in a young patient
|International Journal of Emergency Medicine|2024|1